Blokhin Cancer Research Center

Moscow 115487

0 studies enrolling now · 10 studies all time

What they study most

Advanced Cancer, Biliary Tract Cancer, Breast Cancer, Hepatocellular Carcinoma, Locally Advanced Soft Tissue Sarcoma, Metastatic Cancer, Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer, Metastatic Soft Tissue Sarcoma, Myelodysplastic Syndromes, Prostate Cancer, Soft Tissue Sarcoma

Studies at this site

• A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer — Running, not enrolling
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer — Running, not enrolling
• A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma — Completed
• Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma — Completed
• Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity — Completed
• Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas — Completed
• A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care — Completed
• A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP) — Completed
• MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer — Completed
• T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients — Stopped early